The Testosterone Gap: Why Women Are Being Left Behind in Hormone Care

The medical establishment fails to address testosterone deficiency in women, creating a systemic oversight with serious consequences. Although women produce more testosterone than estrogen, the medical community ignores it in favor of a model that only looks for disease. This issue stems not from a lack of safety data, but from regulatory caution and a lack of standardized, profitable delivery methods. Practitioners and patients gain more by ignoring restrictive international guidelines in favor of evidence based, individualized dosing. Those who focus on hormone optimization rather than waiting for an FDA approved solution improve their cognitive health, metabolic function, and physical performance.

Key Insights & Analysis

The Pathology Only Trap and the Regulatory Void

Medicine has historically treated testosterone as a male hormone, viewing it in women only when a condition like Polycystic Ovarian Syndrome (PCOS) is present. Dr. Susan Hardwick-Smith notes that her medical training provided no instruction on the natural, age related decline of testosterone in healthy women. This creates a blind spot. Because testosterone lacks FDA approval for women, clinicians default to off label protocols that are often restrictive or poorly understood.

Testosterone is actually made in far greater quantities than estrogen and female bodies. That is something that is often missed.

-- Dr. Susan Hardwick-Smith

This void leaves many women suffering from low testosterone for years before menopause. They experience brain fog, anxiety, low libido, and muscle loss, yet the system often dismisses these symptoms. Patients are frequently told they are within range even when they feel physically and mentally depleted.

The Myth of the Standard Delivery Method

The 2019 International Consensus suggests using male dosed gels divided into smaller portions. Hardwick-Smith argues this system is flawed. Topical gels have highly variable absorption rates, often around 10 percent, which leads to unpredictable blood levels.

This creates a cycle of frustration. Physicians see inconsistent results, patients feel no relief, and the clinician concludes that testosterone is ineffective or risky. The problem is the delivery method, not the hormone. Data suggests that stable, physiological levels are easier to achieve through subcutaneous pellets or injections, which avoid the volatility of topical absorption.

Distinguishing Nuisance from Danger

The fear that testosterone causes irreversible changes like voice deepening or hair loss comes from extreme, high dose protocols that ignore the principle that the dose is the poison. Hardwick-Smith notes that these side effects are not sudden. They result from years of over dosing.

It took eight years. So I never blamed the patient however, I said why did you keep going back? And she said, well I felt great.

-- Dr. Susan Hardwick-Smith

This fear fosters a medical culture that denies women access to a hormone that improves bone density, muscle mass, and cognitive clarity. By using safety data from 50 years of transgender hormone therapy, it is clear that risks are manageable and the benefits, such as reduced inflammation and improved athletic performance, are significant.

Key Action Items

• Audit your current hormone status: If you are perimenopausal or postmenopausal and experiencing brain fog, fatigue, or low libido, do not accept a normal lab result based on broad population reference ranges. (Immediate)
• Prioritize Total Testosterone: Recognize that Free Testosterone is often a calculated estimate rather than a direct measurement, making it unreliable. Focus on Total Testosterone as a primary clinical guideline. (Immediate)
• Adopt the N of 1 experimental mindset: Understand that hormone replacement is an individualized process. Start with conservative dosing, such as 1/10th of a typical male dose, and retest in six weeks to establish your unique baseline. (Over the next 6 to 8 weeks)
• Look beyond topical gels: If you are not seeing results or stability with gels, discuss more consistent delivery methods like subcutaneous injections or pellets with a qualified practitioner. (3 to 6 months)
• Monitor for nuisance side effects: Be proactive about tracking minor changes like oily skin or hair growth. These are early, reversible indicators that the dose is too high. Address them early to avoid long term issues. (Ongoing)
• Focus on long term metabolic health: View testosterone not just as a sexual health tool, but as a component for maintaining muscle mass and bone density. This pays off in 12 to 18 months by reducing the risk of sarcopenia and frailty. (12 to 18 months)